Plain-English translation of NCT07035002 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called PD-1 knockout tumor-infiltrating T cells (TILs) for patients with advanced colorectal cancer. Doctors will remove a small piece of your tumor, isolate immune cells from it, and use gene editing to modify them so they can fight your cancer more effectively. The modified cells are then grown in large numbers and given back to you as an infusion.
Cancer cells hide from your immune system by turning off immune cells through a process involving a protein called PD-1. This treatment aims to solve that problem by removing PD-1 from your immune cells before putting them back, so they can recognize and kill cancer cells without being suppressed.
You likely qualify if…
You likely don't qualify if…
First, you will have surgery or a biopsy to remove a sample of your tumor so doctors can isolate immune cells from it. These cells will then be sent to a laboratory where they are modified and grown over several weeks. Once ready, you will receive the cells back as an infusion into your bloodstream. The trial starts with small doses in some patients, then increases the dose in later groups if safety is confirmed. You will have regular follow-up visits to check for side effects and how well the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China